Patents by Inventor Scott Raymond Walker

Scott Raymond Walker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS
    Publication number: 20170283407
    Abstract: A compound of formula (I) wherein: R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.
    Type: Application
    Filed: September 3, 2015
    Publication date: October 5, 2017
    Inventors: Richard Charles Foitzik, Michelle Ang Camerino, Scott Raymond Walker, H. Rachel Lagiakos
  • FAK inhibitors
    Patent number: 9421205
    Abstract: A compound of the formula (I): where R1 or R2 is a cyclic amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: August 23, 2016
    Assignee: Cancer Therapeutics CRC PTY LTD.
    Inventors: Ian Peter Holmes, Yiva Bergman, Gillian Elizabeth Lunnis, Marica Nikac, Neil Choi, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene
  • 2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE
    Publication number: 20160222005
    Abstract: Substituted benzimidazole and 3H-imidazo[4,5-b]pyridines or formula I: where X and Y respectively are selected from: (i) N and N; and (ii) N and CR4; A2 is selected from: a C5 heteroarylene group, containing 2 or 3 ring heteroatoms, where the bonds to L1 and the core are ? to one another; L1 is selected from: (i) A1—O—CH2—A2; (ii) A1—CH2—O—A2; (iii) A1—C(?O)—NH—A2; (iv) A1—CH(OH)—A2; (v) A1—CH2—NH—C(?O)—A2; (vi) A1—S—CH2—A2; (vii) A1—CH2—S—A2; (viii) A1—CH2—A2; and (ix) A1—CH(CH3)—O-A2; A1 is phenyl, optionally substituted by F or CF3; their use as pharmaceuticals, and in particular, in treating cancer and hemoglobinopathies.
    Type: Application
    Filed: February 20, 2014
    Publication date: August 4, 2016
    Inventors: Paul Anthony Stupple, Scott Raymond Walker, Jo-Anne Pinson, Helen Rachel Lagiakos, Gillian Elizabeth Lunniss, Ian Peter Holmes, Alexandra Elizabeth Stupple, Ylva Elisabet Bergman, Richard Charles Foitzik, Wilhelmus Johannes Antonius Kersten, Michelle Ang Camerino
  • Selective FAK inhibitors
    Patent number: 9174946
    Abstract: A compound of the formula (I): where R1 or R2 is a cycle, amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: November 3, 2015
    Assignee: Cancer Therapeutics CRC Pty LTD
    Inventors: Ian Peter Holmes, Yiva Bergman, Gillian Elizabeth Lunniss, Marcia Nikac, Neil Choi, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene
  • Selective FAK inhibitors
    Patent number: 9120761
    Abstract: A compound of the formula (I): where R1 or R2 is a cyclc amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: September 1, 2015
    Assignee: Cancer Therapeutics CRC PTY LTD
    Inventors: Ian Peter Holmes, Ylva Bergman, Gillian Elizabeth Lunniss, Marica Nikac, Neil Chol, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene
  • FAK INHIBITORS
    Publication number: 20150231135
    Abstract: A compound of the formula (I): where R1 or R2 is a cyclic amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Application
    Filed: February 11, 2015
    Publication date: August 20, 2015
    Inventors: Ian Peter Holmes, Yiva Bergman, Gillian Elizabeth Lunnis, Marica Nikac, Neil Choi, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene
  • FAK inhibitors
    Patent number: 9012461
    Abstract: A compound of the formula (I): where R1 or R2 is a cyclc amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: April 21, 2015
    Assignee: Cancer Therapeutics CRC Pty Ltd
    Inventors: Ian Peter Holmes, Ylva Bergman, Gillian Elizabeth Lunniss, Marica Nikac, Neil Choi, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene
  • BINDING AGENT
    Publication number: 20140323346
    Abstract: The present disclosure generally relates to protein binding agents, such as protein kinase binding agents of general Formula (I). The protein binding agents may be provided attached to a solid support and may be used, for example, to detect the presence of a broad range of proteins in a sample. Methods of synthesizing the protein binding agents, and kits comprising the protein binding agents, are also disclosed.
    Type: Application
    Filed: November 21, 2012
    Publication date: October 30, 2014
    Applicant: Garvan Institute of Medical Research
    Inventors: Roger John Daly, Ian Peter Holmes, Ian Street, Scott Raymond Walker
  • SELECTIVE FAK INHIBITORS
    Publication number: 20130324546
    Abstract: A compound of the formula (I): where R1 or R2 is a cycle, amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Application
    Filed: February 17, 2012
    Publication date: December 5, 2013
    Applicant: Cancer Therapeutics CRC Pty Limited
    Inventors: Ian Peter Holmes, Yiva Bergman, Gillian Elizabeth Lunniss, Marcia Nikac, Neil Choi, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene
  • FAK INHIBITORS
    Publication number: 20130324532
    Abstract: A compound of the formula (I): where R1 or R2 is a cyclc amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Application
    Filed: February 17, 2012
    Publication date: December 5, 2013
    Applicant: Cancer Therapeutics CRC Pty Limited
    Inventors: Ian Peter Holmes, Yiva Bergman, Gillian Elizabeth Lunniss, Marcia Nikac, Neil Choi, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene
  • SELECTIVE FAK INHIBITORS
    Publication number: 20130022594
    Abstract: A compound of the formula (I): where R1 or R2 is a cyclc amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Application
    Filed: July 6, 2012
    Publication date: January 24, 2013
    Applicant: Cancer Therapeutics CRC Pty Limited
    Inventors: Ian Peter Holmes, Ylva Bergman, Gillian Elizabeth Lunniss, Marica Nikac, Neil Chol, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene
  • FAK INHIBITORS
    Publication number: 20130017194
    Abstract: A compound of the formula (I): where R1 or R2 is a cyclc amine group and R5 is an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.
    Type: Application
    Filed: July 6, 2012
    Publication date: January 17, 2013
    Applicant: Cancer Therapeutics CRC Pty Limited
    Inventors: Ian Peter Holmes, Ylva Bergman, Gillian Elizabeth Lunniss, Marica Nikac, Neil Choi, Catherine Fae Hemley, Scott Raymond Walker, Richard Charles Foitzik, Danny Ganame, Romina Lessene